share_log

The Strong Earnings Posted By Kangmei Pharmaceutical (SHSE:600518) Are A Good Indication Of The Strength Of The Business

The Strong Earnings Posted By Kangmei Pharmaceutical (SHSE:600518) Are A Good Indication Of The Strength Of The Business

康美药业(SHSE: 600518)公布的强劲收益很好地表明了该业务的实力
Simply Wall St ·  04/21 09:16

Even though Kangmei Pharmaceutical Co., Ltd. (SHSE:600518 ) posted strong earnings, investors appeared to be underwhelmed. We have done some analysis and have found some comforting factors beneath the profit numbers.

尽管康美药业有限公司(SHSE: 600518)公布了强劲的收益,但投资者似乎不知所措。我们做了一些分析,发现利润数字之下有一些令人欣慰的因素。

earnings-and-revenue-history
SHSE:600518 Earnings and Revenue History April 21st 2024
SHSE: 600518 2024 年 4 月 21 日的收益和收入历史记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

To properly understand Kangmei Pharmaceutical's profit results, we need to consider the CN¥76m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Kangmei Pharmaceutical doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

为了正确了解康美药业的利润业绩,我们需要考虑归因于不寻常项目的7600万元人民币支出。看到不寻常的项目使公司利润付出代价从来都不是一件好事,但从好的方面来看,情况可能迟早会好转。当我们分析全球绝大多数上市公司时,我们发现重大不寻常的事项往往不会重演。鉴于这些单列项目被认为不寻常,这并不奇怪。如果康美药业没有看到这些不寻常的支出重演,那么在其他条件相同的情况下,我们预计其利润将在来年增加。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Kangmei Pharmaceutical.

注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对康美药业的资产负债表分析。

Our Take On Kangmei Pharmaceutical's Profit Performance

我们对康美药业利润表现的看法

Because unusual items detracted from Kangmei Pharmaceutical's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Kangmei Pharmaceutical's earnings potential is at least as good as it seems, and maybe even better! And it's also positive that the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about Kangmei Pharmaceutical as a business, it's important to be aware of any risks it's facing. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of Kangmei Pharmaceutical.

由于不寻常的项目削弱了康美药业去年的收益,你可能会争辩说,我们可以预期本季度的业绩会有所改善。正因为如此,我们认为康美药业的盈利潜力至少和看上去一样好,甚至可能更好!在去年亏损之后,该公司表现出了足够的改善,今年实现了盈利,这也是一个积极的因素。归根结底,如果你想正确地了解公司,必须考虑的不仅仅是上述因素。如果您想进一步了解康美药业的业务,了解康美药业面临的任何风险很重要。例如,我们发现了一个警告信号,为了更好地了解康美药业,你应该把视线移过去。

Today we've zoomed in on a single data point to better understand the nature of Kangmei Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我们放大了单一数据点,以更好地了解康美药业利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发